31 results about "Erythromycin resistance" patented technology

A compound of the following formula [1], which possesses good antimicrobial activity against erythromycin-resistant bacteria, such as resistant pneumococci, streptococci and mycoplasma, against which conventional macrolide antibiotics do not possess sufficient antimicrobial activity. Also provided is a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

The invention discloses a building method and application of a lactobacillus reuteri resistance-marker-free gene integration system. By means of the point mutation technology, a point mutation gene pheSM of a lactobacillus reuteri pheS gene is obtained, the point mutation gene pheSM and a erythromycin resistance gene are used for building an integrated framework LR-pheSM-em-RR, the integrated framework LR-pheSM-em-RR is electrically converted into L.renteri XNY competent cells, and pheSM genetic recombination lactobacillus L.renteri XNYM is obtained through erythromycin screening; then, the gene integration framework is constructed and inserted, then the gene integration framework is electrically converted into pheSM gene recombination lactobacillus reuteri competent cells, and the lactobacillus reuteri without resistance markers can be obtained through para-chlorophenylalanine acid resistance screening. According to the method, resistance genes are not introduced into host bacteria genomes, so that biological safety hidden hazards of the resistance genes and the polarity effect of the resistance genes on upstream genes and downstream genes are avoided. By means of the system, gene targeted integration can be carried out on the host bacteria for multiple times.

The present invention relates to a high-throughput detection chip for drug resistance gene of bacteria, and an application thereof. The detection chip comprises 117 gene probes, the drug resistance gene probes are selected from 17 categories of drug resistance genes, which comprise extended spectrum beta-lactamase, cephalosporinase, carbapenemase, integrase gene, tetracycline resistance gene, aminoglycoside resistance gene, disinfectant resistance gene, erythromycin resistance gene, macrolide efflux gene, vancomycin resistance gene, multidrug resistance efflux pump gene, mupirocin resistance gene, sulfanilamide resistance gene, tylosin resistance gene, fluoroquinolone resistance gene, chloramphenicol acetyltransferase and commonly-used genetic engineering vector resistance gene. The chip is adopted for detecting the resistance gene of the pathogenic bacteria. The chip is characterized in that: the chip comprises (1) 117-oligonucleotide probe composition and quality control probes of 17 categories of the drug resistance genes; (2) probe arrays, wherein the oligonucleotide probes are solidified on the vector material through arm molecules to form the probe arrays.

The invention provides a rapid screening system for Lactococcus lactis with knocked-in exogenous genes. The screening system comprises temperature-sensitive plasmids and the Lactococcus lactis, wherein the temperature-sensitive plasmids contain his gene segments and temperature-sensitive replicon-erythromycin resistance gene (Ts-Emr) segments; chromosomes of the Lactococcus lactis contain lacZ gene expression segments. lacZ genes of the Lactococcus lactis cannot be expressed when the exogenous genes are knocked in successfully, so that white colonies are shown on a solid medium containing X-Gal, otherwise, blue colonies are shown, the change from the blue colonies to the white colonies can be directly observed on the solid medium, the screening workload can be greatly reduced, and screening time can be greatly shortened.

A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneunococci and streptococci).

The present invention provides an erythromycin derivative, characterized in that the erythromycin derivative comprises a compound of general formula I, or, the erythromycin derivative comprises a compound of general formula I and an inorganic acid or a pharmaceutically acceptable salt formed from an organic acid, the erythromycin derivatives can be better adapted to industrial production, and can be used against common erythromycin-resistant Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes Pathogenic bacteria such as cocci, Mora catarrhalis and Haemophilus influenzae have good anti-susceptible and anti-drug-resistant bacteria activities, and can effectively treat clinical bacterial pneumonia or other microorganisms (such as mycoplasma, Legionella, etc.) Pneumonia, and other tissue infections;

The invention relates to the application of a gene engineering technology in increasing an antibiotic component, in particular to a gene series technology for increasing the main component content of gene engineering isovaleryl selectomycin. The gene series technology comprises the following steps: connecting ist genes which are closely related to selectomycin isovaleryl acylation in Beta selectomycin gene engineering bacteria in series; increasing the bacterial isovaleryl acylation generating capability by increasing gene dosage; using a promoter erythrocin resistance gene erm promoter sequence with strong promotion activity to replace the original ist gene promoter sequence so as to increase the expression of the series ist genes, and improve the proportion of isovaleryl selectomycin main components of the gene engineering bacteria from a headstream.

The invention pertains to the field of medical technology and relates to engineering bacteria directly producing tobramycin and the application thereof, which mainly damages carboxamide transferase gene in bacteria produced by the tobramycin, therefore the strain does not produce carboxamide tobramycin any more but tobramycin. The invention, by the method of deleting inactivation within the frame, breaks tacA gene in Streptomyces tenebrarius, comprising the composition of the tacA gene breaking plasmid, the breaking of the transformation of plasmid pSPU303 into Streptomyces tenebrarius H6, the screening of double exchange strains, the detection of fermentation products and the identification of new compositions. The method of deleting inactivation within the frame respectively provides two segments with the upper reach molecular weight and the lower reach molecular weight of the tacA gene not less than 500bp for the PCR, both segments are connected to pIJ2925 simultaneously, one end of the segment is connected to resistance gene of antibiotics that is expressible in the Streptomyces tenebrarius such as erythromycin resistance gene ermE, and three gene segments are connected to shuttle vector pHZ132 by using Bg1II Enzyme cutting. The engineering bacteria directly producing tobramycin and the application thereof can simplify the production technology and reduce the production cost, thus facilitating the quality control of the products.

The present invention provides a macrocyclic lactone and quinolone hybrid, characterized in that the macrocyclic lactone and quinolone hybrid include compounds with general formula I and general formula II, or, the macrocyclic lactone and quinolone hybrids include pharmaceutically acceptable salts formed by compounds of the general formula I and II and inorganic acids or organic acids, and the macrolide and quinolone hybrids can be better adapted to industrial production , and has good anti-susceptible and anti-drug resistance against common clinical erythromycin-resistant Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Mora catarrhalis and Haemophilus influenzae Bacterial activity, can effectively treat clinical bacterial pneumonia or pneumonia caused by other microorganisms (such as mycoplasma, Legionella, etc.), and other tissue infections;

The invention provides a preparation method of a porphyromonas gingivalis RgpA gene knock-out mutant strain, and relates to the field of oral medicine. The method includes the steps that upstream and downstream homologous arms of porphyromonas gingivalis RgpA genes are amplified; erythrocin resistance gene segments are amplified; homologous recombination fragments with the upstream and downstream homologous arms of the RgpA genes at the two ends and the erythrocin resistance gene segments in the middle positions are constructed; the homologous recombination fragments are converted into porphyromonas gingivalis, homologous recombination is performed, an erythrocin resistance plate is adopted for screening, and then the porphyromonas gingivalis RgpA gene knock-out mutant strain is obtained. According to the preparation method of the porphyromonas gingivalis RgpA gene knock-out mutant strain, operation is easy, convenient and flexible, no complex enzyme-cut and link-up or screening is needed, no specificity requirement exists in selection of mutation sites, and recombination efficiency is high.

The invention discloses an overexpressed UGPase (UDP-glucose pyrophosphorylase) gene and a method for constructing recombinant lactobacillus acidophilus thereof. The method is characterized by comprising the specific steps as follows: (1) a UGPase gene LBA0625 is amplified with lactobacillus acidophilus genome DNA as a template; an expression vector pMG36e is subjected to single restriction digest with restriction enzyme Hind III, and after dephosphorylation and gel recovery are performed, a recombinant expression vector is constructed by inserting a PCR amplification product into the expression vector pMG36e; (2) an overexpression plasmid subjected to extraction and concentration is imported into lactobacillus acidophilus through electrotransformation, the lactobacillus acidophilus is resuscitated at 37 DEG C for 2 h, applied to an erythrocin resistant plate and cultured at 37 DEG C for 36 h for screening transformants; the transformants are subjected to PCR verification, and the recombinant lactobacillus acidophilus PLY127-1 of the overexpressed UGPase gene is obtained. The freeze-drying survival rate of the lactobacillus acidophilus can be increased substantially.

The invention discloses a series of erythromycin A ketolide antibiotics containing an aminoquinoline ring as shown in formula I, a preparation method and application thereof, side chain intermediates of each compound and a synthesis method. The key points of the present invention are: the compound shown in formula I has broad-spectrum antibiotic efficacy, and has outstanding antibacterial activity to sensitive and drug-resistant Gram-positive bacteria and negative bacteria, especially to vancomycin The antimicrobial activities of antibiotic-resistant Enterococcus faecalis, Enterococcus faecium, erythromycin-resistant Streptococcus pneumoniae, Streptococcus pyogenes, Klebsiella pneumoniae, and Shigella flexneri were significantly better than those of the control drug Telithromycin white. The compound proposed by the invention can be used as a broad-spectrum antibiotic, and has the antibacterial and antiviral activities of inhibiting Gram-positive bacteria and Gram-negative bacteria.